GrifolsGRFS +0.48%84 EBIT per Share is $1.97 as of Mar. 2026. GuruFocus rates GRFS with a GF Score™ of 84/100 and a GF Value™ of $8.87 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 808 Drug Manufacturers companies, Grifols ranks better than 71.78% on this metric.
Grifols's EBIT per Share for the
three
months ended in Mar. 2026 was $0.42.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.97.
During the past 12 months, the average EBIT per Share Growth Rate of Grifols was 1.20% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 22.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 10.50% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -0.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Grifols's EBIT per Share or its related term are showing as below:
GRFS'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -17.2 Med: 10.75 Max: 45.9
Current: 22.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Grifols was 45.90% per year. The lowest was -17.20% per year. And the median was 10.75% per year.
GRFS's 3-Year EBIT Growth Rate is ranked better than 71.78% of 808
companies
in the Drug Manufacturers industry
Industry Median: 7.65
vs GRFS: 22.50
Grifols's EBIT for the
three
months ended in Mar. 2026 was $288 Mil.
Grifols (NAS:GRFS) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Grifols EBIT per Share Related Terms
Grifols EBIT per Share Historical Data
* Premium members only.
The historical data trend for Grifols's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.97
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grifols (GRFS) has a EBIT per Share of $1.97 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Grifols and its competitors. According to the industry distribution chart, Grifols ranks #228 out of 808 companies in the Drug Manufacturers industry, placing it in the top 28.2%.
Is Grifols' EBIT per Share too high?
Grifols' current EBIT per Share is $1.97. The Drug Manufacturers industry median EBIT per Share is 7.65. Grifols' value of $1.97 is 74.2% below this industry median. Based on the distribution chart, Grifols ranks #228 out of 808 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grifols has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grifols' EBIT per Share compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Grifols ranks #228 out of 808 companies for EBIT per Share. This puts Grifols in the upper half of its industry. The industry median EBIT per Share is 7.65. Grifols' value of $1.97 is 74.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.65, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grifols's current EBIT per Share of $1.97 is 74.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Grifols and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grifols's current EBIT per Share is $1.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (GRFS) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.87, compared to a current price of $7.39 — trading 16.7% below its estimated fair value. The current EBIT per Share is $1.97 and 74.2% below the Drug Manufacturers industry median of 7.65. Grifols' overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Grifols (GRFS), the current EBIT per Share is $1.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grifols (GRFS) Overvalued in 2026?
Based on GuruFocus' analysis, Grifols stock appears to be undervalued.
The current stock price of $7.39 is trading 16.7% below its estimated GF Value™ of $8.87.
GuruFocus considers Grifols to be Modestly Undervalued.
Key valuation signals for GRFS:
EBIT per Share: $1.97
GF Value™: $8.87 vs. price of $7.39 (16.7% below fair value)
Industry Position: 74.2% below the Drug Manufacturers median (#228 of 808)
No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
84GF Score
Get the complete analysis for GRFS
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRFS has been successfully added to your 
